The company's monoclonal antibody targets and kills cancer cells with fewer side effects than conventional chemotherapies. It is designed to treat relapsed or refractory T-cell ALL and other IL-7R expressing cancers. Allterum Therapeutics is also exploring the use of the antibody to treat relapsed/refractory solid tumors with IL-7R over-expression. The 4A10 antibody was licensed exclusively to Fannin Innovation Studio after being developed at the National Cancer Institutes (NCI).